Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Bispecific CD19/22 CAR therapy in children and young adults with ALL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 17.12.18
Views: 877

Dr Liora M Schultz - Stanford University, Palo Alto, USA

Dr Liora Schultz speaks to ecancer at ASH 2018 about the use of bispecific CD19/CD22 CAR therapy in children and young adults with B Cell acute lymphoblastic leukaemia.

She explains that while the monospecific CAR field has had a lot of exciting advancements, long term outcomes have not been correlating with the initial complete remissions.

Dr Schultz concludes by talking about the next steps for the study and her hopes of being able to target their CAR products further.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation